An interventional study of PRX S topical cosmetic treatment and WiQo home care regimen (Nourishing Cream; Balancing Cream) in Acne-prone Skin and Skin Disease, sponsored by WiQo S.p.A.. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by WiQo S.p.A. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 202 studies in Skin Diseases with a site in United States — 32 open to participants now, 49 under way, 9 of them phase 3. Skin Diseases · United States.
Among the 202 studies in Skin Diseases with a site in United States, this one is the 124th largest by planned enrollment of the 172 interventional ones that give a count, is one of 11 that started in 2026, is one of 33 with no phase, reaches primary completion later than 14 of the 48 other live ones, and was the 202nd registered.
497 studies on the registry are indexed under Skin Diseases; 78 are open to participants now.
Browse Skin Diseases studies →32 of the 202 studies in Skin Diseases with a site in United States are open now. Recruiting first, the newest first:
Spyre Therapeutics, Inc. · Sites in United States, Canada
Ages 18–75
IAS Skin Care · Sites in United States
Ages 25–65 · Women only · Healthy volunteers
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
Pfizer · Sites in United States, Canada, Japan
Ages 12+
Apollo Therapeutics Ltd · Sites in United States, Bulgaria, Canada and 5 more countries
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 55 Skin Diseases studies recruiting now, 27 (49%) set no upper age limit and 18 (33%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
202 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 69 · Phase 3 46 · Phase 4 8
First in 1978; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 70 across 375 interventional studies indexed under Skin Diseases.
Median enrollment 99 across the 172 interventional studies, 298 across the 28 observational. Of the 142 that completed or were terminated, 90 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
139 of 202 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with WiQo S.p.A. as lead sponsor.
WiQo S.p.A. has 1 study filed under Skin Diseases — fewer than ten, so there is no comparison to draw.
19 of the studies in Skin Diseases with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07144345Phase 3Sun Pharmaceutical Industries, Inc.Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp | 2027-01 |
| NCT07144852Phase 3Sun Pharmaceutical Industries, Inc.Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities | 2027-01 |
| NCT07717346Krystal Biotech, Inc.A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease | 2026-11 |
| NCT06674980C5 BiomedicalClinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs | 2026-11-22 |
| NCT07866131WiQo S.p.A.Observational Assessment of Skin Appearance Changes During PRX S Cosmetic Treatment in Participants With Acne-Prone Skin | 2026-12 |
Add all 19 to your calendar (.ics) → With an account.
Among the 202 studies in Skin Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This pilot cohort study evaluates changes in skin surface appearance in adult participants with acne-prone skin during and following a standardized five-session course of PRX S (WiQo SpA), a topical cosmetic product designed for oily and acne-prone skin.
The study asks whether a standardized in-office PRX S treatment cycle - five sessions administered at two-week intervals and complemented by a prescribed home care regimen - is associated with observable changes in objective skin surface parameters (pore appearance, texture, spots, redness, porphyrins), clinician-rated acne severity (IGA, GAGS), and participant-reported skin-related quality of life (QoL-RA) in adults with acne-prone skin.
Using a single-group, pre-post observational design across two U.S. sites (Leawood, KS and Tulsa, OK), 30 participants will undergo VISIA complexion analysis and clinical assessments at baseline (T0), mid-cycle (T1, Week 6), and end of follow-up (T2, Week 10). No single primary endpoint is designated; all analyses are explicitly exploratory.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: PRX S topical cosmetic treatment · Other: WiQo home care regimen (Nourishing Cream; Balancing Cream)
PRX S (WiQo SpA, Milan, Italy) is a topical cosmetic formulation designed for acne-prone and oily skin. It is applied in-office by trained aesthetic professionals or dermatologists using a proprietary non-ablative technique with no visible peeling or downtime. Five sessions are administered at two-week intervals (Weeks 0, 2, 4, 6, 8). The application procedure is adapted to the participant's skin presentation: Procedure 1 for oily skin with enlarged pores; Procedure 2 for comedone-predominant presentations. PRX S is supplied directly to study sites by the Sponsor free of charge.
A standardized daily home care regimen prescribed in conjunction with in-office PRX S sessions, consisting of two commercially available cosmetic products supplied by the Sponsor: WiQo Nourishing Cream for Normal and Combination Skin (applied each morning) and WiQo Balancing Cream (applied each evening). The Balancing Cream contains micronized azelaic acid, encapsulated salicylic acid, fermented botanical extracts, and niacinamide. Both products are supplied to participants free of charge for the duration of the study.
Change in VISIA Pores Score
Objective pore assessment performed by VISIA Complexion Analysis system (Canfield Scientific, Parsippany, NJ). The score is a normalized index relative to an age- and phototype-matched reference population. Lower scores indicate fewer visible pores relative to the reference population and represent a better outcome.
Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)
Change in VISIA Spots Score
Objective spot assessment performed by VISIA Complexion Analysis system (Canfield Scientific, Parsippany, NJ). The score is a normalized index relative to an age- and phototype-matched reference population. Lower scores indicate fewer visible spots relative to the reference population and represent a better outcome.
Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)
Change in VISIA Red Areas Score
Objective assessment of red area extent performed by VISIA Complexion Analysis system (Canfield Scientific, Parsippany, NJ) using RBX® Red channel imaging. The score is a normalized index relative to an age- and phototype-matched reference population. Lower scores indicate reduced surface redness relative to the reference population and represent a better outcome.
Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)
Change in VISIA Porphyrins Score
Objective porphyrin assessment performed by VISIA Complexion Analysis system (Canfield Scientific, Parsippany, NJ) using UV fluorescence photography. The score is a normalized index relative to an age- and phototype-matched reference population. Lower scores indicate fewer porphyrins relative to the reference population and represent a better outcome.
Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)
Change in VISIA Texture Score
Objective skin texture assessment performed by VISIA Complexion Analysis system (Canfield Scientific, Parsippany, NJ). The score is a normalized index relative to an age- and phototype-matched reference population. Lower scores indicate smoother skin texture relative to the reference population and represent a better outcome.
Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)
Change in Investigator Global Assessment (IGA) Score
Clinician-rated acne severity assessed using the Investigator Global Assessment (IGA) scale, a 5-point ordinal scale ranging from 0 to 4 (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe). Lower scores indicate less severe acne and represent a better outcome. The T0 value serves as individual reference.
Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)
Change in Global Acne Grading System (GAGS) Score
Clinician-rated acne severity assessed using the Global Acne Grading System (GAGS), a weighted scoring instrument that evaluates acne lesion type and distribution across six facial and truncal regions (forehead, right cheek, left cheek, nose, chin, and chest/back). Total scores range from 0 to 44: 0 = no acne; 1-18 = mild; 19-30 = moderate; 31-38 = severe; \>38 = very severe. Lower scores indicate less severe acne and represent a better outcome. The T0 value serves as individual reference.
Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)
Change in Quality of Life Relevance-Acne (QoL-RA) Score
Participant-reported acne-related quality of life assessed using the Quality of Life Relevance-Acne (QoL-RA) questionnaire (Chernyshov et al., JAAD International, 2024). The QoL-RA is a 19-item self-reported instrument covering 3 dimensions: Socioemotional (11 items), Symptoms (4 items), and Stigma and Suicidal thoughts (4 items). Each item is rated on a 4-point scale (0 = Never; 1 = Rarely; 2 = Sometimes; 3 = Frequently); total scores range from 0 to 57. Higher scores indicate greater HRQoL impairment and represent a worse outcome.
Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)
Treatment Tolerability
Incidence and type of adverse events and product-related tolerability findings across all 5 treatment sessions.
Time frame: Through study completion (Week 10)
VISIA Acne-Prone Skin Composite Index (VISIA-APS)
Pre-specified composite summary index computed as the mean of the z-scores of the five principal VISIA parameters (pores, spots, red areas, porphyrins, and texture), standardized using the sample mean and SD at baseline (T0). The direction of each z-score is pre-specified so that positive values consistently indicate improvement. The VISIA-APS has no fixed minimum or maximum; higher values indicate greater overall improvement across all five acne-prone skin parameters and represent a better outcome.
Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)
VISIA Wrinkles Score
Objective wrinkle assessment performed by VISIA Complexion Analysis system (Canfield Scientific, Parsippany, NJ). The score is a normalized index relative to an age- and phototype-matched reference population. Lower scores indicate fewer visible wrinkles relative to the reference population. This parameter is reported descriptively only and is not included in formal inferential analyses.
Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)
Plan to share: No — Individual participant data will not be shared. All data collected in this study are proprietary to the Sponsor (WiQo SpA) and are subject to applicable data privacy and protection regulations, including the EU General Data Protection Regulation (GDPR) and applicable U.S. state privacy laws. No IPD sharing is planned.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.
Of 53 industry-sponsored interventional studies with no phase under Skin Diseases, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's planned 3 months is close to that.
Counting every sponsor, half of 95 studies reached it within 7 months; a quarter within 2 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.